statistiche ricercatore

Continente	#
EU - Europa	2.219
NA - Nord America	789
AS - Asia	544
SA - Sud America	91
Continente sconosciuto - Info sul continente non disponibili	30
AF - Africa	23
Totale	3.696

Nazione	#
FI - Finlandia	1.893
US - Stati Uniti d'America	765
SG - Singapore	200
IT - Italia	119
CN - Cina	110
BR - Brasile	71
VN - Vietnam	62
PL - Polonia	47
DE - Germania	42
HK - Hong Kong	40
TW - Taiwan	40
GB - Regno Unito	26
BD - Bangladesh	23
FR - Francia	17
JP - Giappone	15
CA - Canada	14
RU - Federazione Russa	14
ID - Indonesia	13
TR - Turchia	11
IN - India	10
UA - Ucraina	9
SE - Svezia	8
AT - Austria	6
BE - Belgio	6
CO - Colombia	6
MX - Messico	6
NL - Olanda	6
AR - Argentina	5
DK - Danimarca	5
EG - Egitto	5
ES - Italia	5
ZA - Sudafrica	5
ET - Etiopia	4
IQ - Iraq	4
VE - Venezuela	4
AL - Albania	3
EC - Ecuador	3
JO - Giordania	3
KE - Kenya	3
LT - Lituania	2
MY - Malesia	2
PK - Pakistan	2
PY - Paraguay	2
RO - Romania	2
TN - Tunisia	2
UZ - Uzbekistan	2
AE - Emirati Arabi Uniti	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
BB - Barbados	1
CH - Svizzera	1
CR - Costa Rica	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DZ - Algeria	1
EE - Estonia	1
GR - Grecia	1
HU - Ungheria	1
IS - Islanda	1
KW - Kuwait	1
KZ - Kazakistan	1
LB - Libano	1
LV - Lettonia	1
MA - Marocco	1
MU - Mauritius	1
PR - Porto Rico	1
SD - Sudan	1
SK - Slovacchia (Repubblica Slovacca)	1
TH - Thailandia	1
TT - Trinidad e Tobago	1
Totale	3.666

Nome	#
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study	2.097
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial	338
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy	301
Core needle biopsy in invasive breast cancer prognostic/predictive power: concordance with surgical speciemen and impact of immunophenotypes	208
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study	170
ErbB2‐NOTCH1 axis controls autophagy in cardiac cells	169
The Value of Semiquantitative Parameters Derived from 18F-FDG PET/CT for Predicting Response to Neoadjuvant Chemotherapy in a Cohort of Patients with Different Molecular Subtypes of Breast Cancer	160
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer	132
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)	121
Totale	3.696

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	54	4	8	5	3	1	1	7	3	2	5	3	12
2022/2023	76	8	8	3	7	8	10	5	11	10	1	5	0
2023/2024	76	1	12	4	1	7	11	2	2	1	6	16	13
2024/2025	308	6	12	23	11	30	30	10	14	57	28	45	42
2025/2026	2.830	87	41	64	85	128	70	114	79	1.946	100	73	43
2026/2027	43	43	0	0	0	0	0	0	0	0	0	0	0
Totale													3.696

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara